The study aimed to investigate the impact of tenofovir amibufenamide (TMF) on blood lipid profiles in chronic hepatitis B (CHB) patients over 48 weeks. 91 CHB patients were divided into two groups based on baseline lipid levels. Results showed that after 48 weeks of TMF treatment, there was no significant change in lipid indices compared to baseline. Additionally, viral suppression rates in treatment-naïve patients improved over time. Cellular experiments also indicated that TMF did not affect lipid metabolism in primary hepatocytes. In conclusion, TMF treatment for CHB patients did not have a significant impact on blood lipids.
Source link
Tenofovir amibufenamide does not alter lipid levels in patients with chronic hepatitis B
